SELVAS Healthcare
At a glance
SELVAS Healthcare filed 20 disclosures in the last 12 months, including 5 5% holder and 1 insider. The most recent key filing was on Jul 9.
Revenue for 2025 was ₩30.8B, down 2.8% on 2024. It made an operating loss of ₩161.6M. Debt was 11% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩14.8B and operating profit of ₩1B.
The 2025 annual report lists 139 employees with an average tenure of 7.3 years and average pay of ₩49.5M, #1467 of 1,829 listed companies by average pay. Its 5 directors and auditors were paid ₩181.9M each on average. It paid no cash dividend for 2025. (주)셀바스에이아이 and related parties held 39.66% at year end.
From the 2025 annual report
Staff: 139 (100 men, 39 women), of whom 11 on fixed-term contracts. Total pay for the year: ₩6.9B. Directors and auditors: 5, paid ₩909.6M in total.
No cash dividend was paid for 2025.
Largest shareholder
(주)셀바스에이아이 holds 38.08%; with 2 related parties the group holds 39.66% of common shares at year end (from 40.48% at the start of the year).
Auditor: 한영회계법인 · opinion: Unqualified.
Source: 2025 annual business report (DART). How figures are combined
Financial summary
Key filings
Other filings
Links open the original filing on DART, in Korean.